REMEDY.HE Stock — Price, Charts & Analysis

Remedy Entertainment Oyj (REMEDY.HE) has no trailing P/E shown and a forward P/E of 25.37x. This places REMEDY.HE in a premium earnings multiple territory based on the valuation data currently available on Worldtickers.

REMEDY.HE trades with 25.37x earnings on Worldtickers. Use valuation together with growth, balance sheet strength, and risk before deciding whether REMEDY.HE looks overvalued or undervalued.

REMEDY.HE's P/E of 25.37x should be judged against Communication Services peers, growth rate, margins, and balance sheet quality. A lower P/E may indicate value, while a higher P/E often means investors expect stronger future growth.

REMEDY.HE's trailing EPS is -€1.16 and forward EPS is €0.69.

EPS, or earnings per share, shows how much profit Remedy Entertainment Oyj generated for each share. REMEDY.HE's trailing EPS is -€1.16, and investors usually prefer EPS that is positive and growing over time.

Remedy Entertainment Oyj has a market cap of €236.20M, making REMEDY.HE a small-cap stock based on the current market value shown on Worldtickers.

REMEDY.HE's latest stock price on Worldtickers is €17.38. The latest move is -€0.14 or -0.80%. Use the live quote, chart, volume, and 52-week range to judge the current trading context.

REMEDY.HE's quote includes a latest price of €17.38. The market open is €17.54. Previous close is €17.52. The intraday range is €17.24 to €17.56.

REMEDY.HE is down in the latest quote, with a move of -€0.14 or -0.80%. To understand the reason, compare this move with news, earnings updates, analyst changes, sector performance, and market-wide direction.

REMEDY.HE generated €52.50M in trailing revenue. Revenue growth is -40.00%, which helps show whether demand is expanding or slowing.

REMEDY.HE's revenue growth is -40.00%, which is a negative demand signal in the latest available data. Investors usually compare revenue growth with margin trends and valuation to judge whether growth is profitable.

No, REMEDY.HE does not show positive profitability metrics in the latest data available on Worldtickers. Net income to common shareholders is -€15.82M.

Gross margin is 83.46%. Margins show how efficiently Remedy Entertainment Oyj turns revenue into profit.

Remedy Entertainment Oyj carries €17.84M and holds €29.60M in cash.

REMEDY.HE holds €29.60M on its balance sheet.

REMEDY.HE's book value per share is €4.04.

Institutions hold 20.37% of REMEDY.HE shares. Insiders hold 40.48% of shares. Ownership mix helps investors understand how much of Remedy Entertainment Oyj is held by professional investors and company insiders.

REMEDY.HE has 13.59M shares outstanding. Float shares are 9.83M. Share count affects market cap, EPS, ownership percentages, and the impact of buybacks or dilution.

Insider activity can be useful context for REMEDY.HE, especially when multiple executives buy shares with their own money. Insider selling is harder to interpret because executives may sell for taxes, diversification, or planned compensation reasons.

Forward EPS for REMEDY.HE is €0.69. Revenue growth is -40.00%. For earnings, investors usually watch EPS, revenue, margins, guidance, and management commentary.

REMEDY.HE's trailing EPS is -€1.16. Forward EPS is €0.69. Use the earnings section on the page to compare reported results, estimates, and trend changes when those datasets are available.

REMEDY.HE is in the Communication Services sector. Its earnings multiple is 25.37x. Its latest displayed growth metric is -40.00%. Compare these figures with sector peers before deciding whether Remedy Entertainment Oyj is stronger or weaker than average.

REMEDY.HE trades at €17.38. The stock trades at 25.37x earnings. Whether to invest depends on your risk tolerance, time horizon, diversification, and view of Remedy Entertainment Oyj's fundamentals.

REMEDY.HE risks include company execution, valuation, competition in Communication Services, interest rates, and broad market volatility. Beta is 1.07, which helps estimate market sensitivity. No single stock should be evaluated without portfolio context.

REMEDY.HE should be compared with companies in Electronic Gaming & Multimedia. Its earnings multiple is 25.37x. Useful comparison points include revenue growth, margins, debt, cash flow, valuation, analyst targets, and price momentum.

Remedy Entertainment Oyj (REMEDY.HE) operates in Communication Services, specifically Electronic Gaming & Multimedia. Remedy Entertainment Oyj, a video game company, engages in the development and sale of PC and console games in Finland. It primarily creates story-driven and action games. The company also offers franchises under the Control, Alan Wake, and Max Payne brand names. Remedy Entertainment Oyj was incorporated in 1995 and is headquartered in Espoo, Finland.

REMEDY.HE trades on Helsinki. Exchange context matters because trading hours, liquidity, currency, and settlement rules can differ across markets.

REMEDY.HE stock is priced in EUR on Worldtickers. Currency matters for international investors because exchange-rate moves can affect local-currency returns.

Remedy Entertainment Oyj's official website listed on Worldtickers is www.remedygames.com. Investor relations pages are useful for earnings releases, annual reports, filings, and shareholder presentations.

Remedy Entertainment Oyj employs about 379 people based on the latest company profile data available on Worldtickers. Workforce size helps investors understand company scale and operating complexity.

Remedy Entertainment Oyj is headquartered in Espoo, Finland. Headquarters location can matter for currency, regulation, tax, labor market, and regional economic exposure.

REMEDY.HE is in the Communication Services sector and the Electronic Gaming & Multimedia industry. Sector context helps investors compare valuation, growth, margins, and risk against similar companies.

REMEDY.HE has traded between €11.06 and €17.96 over the past 52 weeks. At €17.38, it is 3.23% below the high and 57.14% above the low. The 52-week range helps gauge long-term price momentum.

REMEDY.HE is above both its 50-day and 200-day moving averages, which is a common uptrend signal. Its 50-day moving average is €15.21 and its 200-day moving average is €14.21.

REMEDY.HE's RSI is 66.64. Readings below 30 are commonly viewed as oversold, above 70 as overbought, and the current reading suggests a neutral momentum setup.

REMEDY.HE's latest RSI reading is 66.64, which points to neutral momentum today. Traders usually confirm RSI with volume, trend, and nearby support or resistance.

Key support for REMEDY.HE is near €14.68. Key resistance is near €17.96. Breaks above resistance or below support can change the short-term technical setup.

REMEDY.HE's nearest reported support level is €14.68. A clean break below support can weaken the short-term setup, while repeated bounces can show demand.

REMEDY.HE's nearest reported resistance level is €17.96. A breakout above resistance can improve momentum, especially when volume confirms the move.

REMEDY.HE trades about 26.84K shares daily on average. The latest displayed volume is 8.26K shares. Volume helps show liquidity and whether trading interest is unusually high or low.

REMEDY.HE's MACD is 0.12, which is a positive momentum reading. MACD should be reviewed with price trend, moving averages, RSI, volume, and support or resistance levels.

REMEDY.HE is above both its 50-day and 200-day moving averages, which is a common uptrend signal. RSI is 66.64 (neutral). MACD is bullish. Nearest support is around €14.68. Resistance is around €17.96. A buy decision should also consider valuation, earnings quality, risk tolerance, and position sizing.

MA20 is €16.19 (8.23% from price). MA50 is €15.21 (15.17% from price). MA200 is €14.21 (23.33% from price). The moving-average stack helps separate short-term momentum from long-term trend risk.

The server report currently confirms daily moving-average levels rather than a separate EMA-only value. REMEDY.HE's MA20 is €16.19. MA50 is €15.21. For EMA-specific overlays, use the live chart indicators and compare EMA direction with RSI, MACD, volume, support, and resistance.

REMEDY.HE's pivot is near €17.44. Support is near €14.68. Resistance is near €17.96. Price holding above pivot can support a constructive setup, while rejection near resistance can cap momentum.

The next lower support zone for REMEDY.HE is near €16.00. These levels help define risk and possible follow-through zones after a breakout or breakdown.

REMEDY.HE's Bollinger range is roughly €14.18 to €18.20. Band width is near 24.83%. Price near the upper band can show stretched upside momentum, while price near the lower band can show downside pressure or a possible mean-reversion zone.

REMEDY.HE's ATR-based typical daily range is about 3.39%. ATR helps size risk because wider ranges usually require wider stops or smaller position sizes.

Latest volume is 8.26K shares. Average volume is about 26.84K shares. Breakouts with rising relative volume are usually more reliable than moves on light participation.

REMEDY.HE's all-time high shown on Worldtickers is €49.90. Its all-time low is €5.60. All-time levels provide long-range context, but recent fundamentals and market conditions matter more for current decisions.

REMEDY.HE has a beta of 1.07, meaning it has historically been more volatile than the broad market. Beta is useful for judging how much a stock may move during broad market swings.